(Q38540022)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

review article

1 reference

title

OCT1 and imatinib transport in CML: is it clinically relevant? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

D B Watkins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

1 reference

9 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

1960-1969

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26122430%20AND%20SRC:MED&resulttype=core&format=json

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

hOCT 1 and resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Correlation between Imatinib Trough Concentration and Efficacy in Chinese Chronic Myelocytic Leukemia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Interaction of imatinib with human organic ion carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

The SLC22 drug transporter family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Regulation of organic cation transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Proteomics. Tissue-based map of the human proteome

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FLEU.2015.170

21 January 2018

12 December 2020

Comparing protein abundance and mRNA expression levels on a genomic scale

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Correlations between RNA and protein expression profiles in 23 human cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Transcriptional regulation of murine Slc22a1 (Oct1) by peroxisome proliferator agonist receptor-alpha and -gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Natural variation in human membrane transporter genes reveals evolutionary and functional constraints

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Polymorphism in human organic cation transporters and metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Functional variants of OCTN cation transporter genes are associated with Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Characterization of the organic cation transporter SLC22A16: a doxorubicin importer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Transport of monoamine transmitters by the organic cation transporter type 2, OCT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Cloning and characterization of two human polyspecific organic cation transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.170

Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine

21 January 2018

1 reference

12 December 2020

Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia

1 reference

12 December 2020

Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?

1 reference

12 December 2020

Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney

1 reference

12 December 2020

Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance

1 reference

12 December 2020

Peroxisome proliferator–activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells

1 reference

12 December 2020

Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa)

1 reference

12 December 2020

Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations

1 reference

12 December 2020

A systematic review of genetic polymorphisms and breast cancer risk.

1 reference

12 December 2020

Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.

1 reference

12 December 2020

Cloning and functional expression of a human liver organic cation transporter

2 references

12 December 2020

https://api.crossref.org/works/10.1038%2FLEU.2015.170

7 January 2021

inferred from DOI database lookup

Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1)

1 reference

12 December 2020